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How long does biomedical research take?
Studying the time taken between biomedical and
health research and its translation into products,
policy, and practice
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Abstract
Background: The time taken, or ‘time lags’, between biomedical/health research and its translation into health
improvements is receiving growing attention. Reducing time lags should increase rates of return to such research.
However, ways to measure time lags are under-developed, with little attention on where time lags arise within
overall timelines. The process marker model has been proposed as a better way forward than the current focus on
an increasingly complex series of translation ‘gaps’. Starting from that model, we aimed to develop better methods
to measure and understand time lags and develop ways to identify policy options and produce recommendations
for future studies.
Methods: Following reviews of the literature on time lags and of relevant policy documents, we developed a new
approach to conduct case studies of time lags. We built on the process marker model, including developing a
matrix with a series of overlapping tracks to allow us to present and measure elements within any overall time lag.
We identified a reduced number of key markers or calibration points and tested our new approach in seven case
studies of research leading to interventions in cardiovascular disease and mental health. Finally, we analysed the
data to address our study’s key aims.
Results: The literature review illustrated the lack of agreement on starting points for measuring time lags. We
mapped points from policy documents onto our matrix and thus highlighted key areas of concern, for example
around delays before new therapies become widely available. Our seven completed case studies demonstrate we
have made considerable progress in developing methods to measure and understand time lags. The matrix of
overlapping tracks of activity in the research and implementation processes facilitated analysis of time lags along
each track, and at the cross-over points where the next track started. We identified some factors that speed up
translation through the actions of companies, researchers, funders, policymakers, and regulators. Recommendations
for further work are built on progress made, limitations identified and revised terminology.
Conclusions: Our advances identify complexities, provide a firm basis for further methodological work along and
between tracks, and begin to indicate potential ways of reducing lags.
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Background
The time taken, or ‘time lags’, between biomedical and
health research and its translation into interventions that
lead to health and wider benefits is a topic of growing
interest and investment by those concerned to maximise
the returns from such research [1-3]. Once innovations
have been produced, then aspects of their diffusion have
long been studied [4-10] using a wide range of disciplin-
ary approaches [11].
The literature exploring the full time lags between
early research and the eventual translation into health
gains is less extensive than that focussing specifically on
the diffusion of innovations. Key questions remain to be
addressed. Balas and Boren [12], Grant et al. [13], and
Wratschko [14] all estimated a time lag between research
and clinical practice of 17 years, but did so while measur-
ing different, if overlapping, parts of the process. Such
convergence around an ‘average’ time of 17 years hides
complexities that are relevant to policy and practice and
would benefit from greater understanding. Morris et al.
[15] summarised the existing literature and found that the
variation in choice of measures (often proxies for the time
between research and its translation) meant that studies
were rarely measuring the same thing; this variation made
aggregation, comparisons, and generalisations difficult.
Furthermore, little attention appears to have been given to
understanding where within the overall timeline the time
lags are most likely to occur, and the variations that arise.
Existing models of research translation typically refer
to the concept of one or more translation ‘gaps’ along
the overall pathway [2], but how these gaps are defined
differs significantly between approaches and can lead to
results not being comparable between studies. An alterna-
tive approach has been proposed in the “process marker
model” developed by Trochim et al. [16]. Here, specific
research translation milestones or events are considered
to be process markers, and are clearly defined to enable
comparability. Durations can then be assessed between
these markers.
Developing improved ways of measuring time lags is
important because, as Buxton et al. [3] quantified in a
previous study, shortening timescales from research to
benefits increases the rates of return achieved from the
resources invested in research, other things being equal.
There is the risk, however, of inappropriate attempts to
reduce timescales unless there is a proper understanding
of the true nature and variation of time lags in the trans-
lation of health research. For example, there is a need to
acknowledge that it is important to test the safety, effi-
cacy, effectiveness, and value of health care innovations,
and this testing takes time.
The development of medicines is a major area where
various phases of research and development are neces-
sary, and the time taken to develop new medicines is an
issue of considerable concern, not least because of its
impact on costs [17]. The literature on development times
for medicines suggests that durations between Phase I and
Phase III clinical trials have changed little over time, but
there are significant differences between different therapy
areas [18-21]. Some suggested ways to reduce the time
taken to translate research raise questions about whether
the changes merely result in the time being reduced for
some interventions at the expense of lengthening it for
others, as a result of prioritising the translation of one
intervention over another.
There is, therefore, considerable potential value in fur-
ther analysis of time lags in order to generate increased
understanding of the range of factors at work. In the
study reported here, we set out to analyse the best ways
of conducting further analysis of time lags between re-
search and its translation into improved health care, and
decided to develop and use a case study approach, build-
ing on the insights from Trochim et al. [16]. The specific
objectives included i) developing methods to facilitate
improved measurement, and enhanced understanding,
of the diverse nature and causes of time lags across dif-
ferent medical fields and types of interventions; ii) devel-
oping ways to identify factors that speed up translation
of research and options for addressing key policy con-
cerns with the long-term objective of achieving the more
rapid health and economic gains that could result from
faster translation of research into practice; iii) provide a
sounder basis for the assessment of the rate of return on
the investment of biomedical and health research; and iv)
making recommendations for further possible studies.
We adopted a range of methods. First, we conducted
two brief reviews. These reviews covered i) the literature
on time lags, and ii) relevant policy documents and re-
ports. Second, we developed a new approach to conduct-
ing case studies of time lags that started from the process
marker model but built on it in significant ways – since
this is a methodological study we describe the new ap-
proach in some detail. Third, we applied and tested our
new approach in seven case studies of interventions in
cardiovascular disease (CVD) and mental health. Fourth,
we developed a range of approaches to analyse the data
gathered.
The Results and discussion section presents the find-
ings from our reviews of both the literature and the pol-
icy documents, before describing the progress made in
the seven case studies conducted to test the applicability
of the methods developed. As part of this, we describe
how far the cases can be reported using the matrix we de-
veloped to aid comparability of research findings. We then
analyse how far the findings enable us to address the spe-
cific objectives of the study. Finally, we make recommen-
dations for future analysis of the time taken to translate
biomedical and health research into practice.
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Methods
In this methodological study there was considerable iter-
ation between the methods at various stages and emer-
ging findings. Inevitably, the whole process was more
complex than is presented here, but we set out key fea-
tures of the approaches developed and applied.
Reviews of the literature on estimations of time lags and
the potential policy responses to the problem of
excessive time lags
The objective of the literature review was to inform the
overall study as to what had previously been claimed
about the length and nature of time lags. The review
aimed to do this by updating the review by Morris et al.
[15] of the literature describing and quantifying time lags
in the health research translation process, and expanding
it to cover areas relevant for the private sector. The (non-
systematic) search strategy was adapted from O’Neill [22]
and conducted using Google Scholar, Web of Science,
PubMed, and EBSCO, based on key words. Potentially
relevant publications were identified through a two-step
bootstrapping approach. In the first step, we adopted the
same key words used in Morris et al. [15] to define “time
lags”, and the words suggested by the team’s experience to
define “research” and “private sector”. In the second step,
the key words were adjusted to identify the more relevant
hits based on titles.
The primary purpose of the review of policy documents
was to identify perceived reasons for lags and some mea-
sures that have been taken to reduce lags where they were
deemed excessive. From the outset we realised that while
relevant research could be international, when it came to
regulations and policies we would have to have a primarily
UK focus so as to keep the project within budget and
timescale. Drawing on the team’s existing knowledge of
the field, key UK policy documents from 2002 were identi-
fied (plus major US documents they cited). Each docu-
ment was searched for the terms: lag, delay, accelerate,
speed, and time. Discussions in each document were then
summarised, with selected quotes, under the headings:
‘reasons for time lags’ and ‘policy measures to address’.
Subsequently, the key lags discussed in each document
were mapped onto the various tracks (or stages/phases) of
the translation process that were developed in the matrix
described below.
Development of concepts and tools for conducting case
studies and presenting findings on time lags
There are currently few methods that can be applied
directly when undertaking case studies on time lags. We
therefore drew on the experience of team members in
conducting case study research of the impact from health
research [23-25], and in analysing medicines development
pathways [17].
Analysis of process marker model and identifying areas for
amendment
Based on the above experience, we analysed the advantages
and disadvantages of using the process marker model as
the framework for conducting detailed case studies. We
concluded that the process marker model, as it stood,
would not meet the needs of our research. We present the
key aspects of our analysis of the process marker model
here, before describing the methods we went on to develop.
In the Results and discussion section we further analyse the
contribution of the various methods considered.
Trochim et al. [16] identified various ways in which
their process marker model is helpful. Namely, it provides
a more consistent way of analysing the research and trans-
lation process than the multiple models and translation
gaps (“T gaps”) proposed by others; it provides a way of
avoiding unnecessary debate about the start point of the
overall process because its main focus is on the processes
between the first and last markers chosen to be measured;
and it provides opportunities for detailed study of small
segments of the overall timeline that can then be com-
bined if required. Furthermore, a key element of the
Trochim model is the series of ‘operationally definable’
markers which are the milestones or events in the ‘re-
search-practice translation continuum’, each of which ‘can
be operationalized as a specific date’ ([16], pp. 159–160).
Finally, the model suggests three levels of process with the
top level including the full range of the continuum from
the basic research system on the left hand side, to the
right hand side that depicts ‘translation to practice and
policy, and ultimately use in populations and the health
of the public’ ([16], p. 159). The markers at this top level
include pilot proposal submitted, pilot study publica-
tion, first study in animals, first study with humans,
Phase II clinical trial started, patent applied for, Food
and Drug Administration approval, inclusion in re-
search synthesis, dissemination research is included in
health policy, and health impacts measured. Then, more
markers are suggested for the two more detailed levels
below the top level.
However, in planning to apply the process marker
model to our case studies, including a number of non-
pharmaceutical interventions, we found that a full analysis
of a timeline using the range of process markers illustrated
in Trochim et al. [16] would require the collection of un-
feasibly large amounts of data which, even if available,
would take a lot of time and resources. Further, as pre-
sented, the model appears to assume there will be one key
study at each stage of the process; we found that this is a
more reasonable assumption for interventions, such as a
specific medicine, than it is for others, such as psycho-
social type interventions, for some of which there was a
family of studies spanning a wide range of times. Add-
itionally, the model does not explicitly recognise the
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international nature of much of the relevant research and
the challenges of tracking and capturing it. While Trochim
et al. [16] recognise that the research and translation
process is complex and there may be feedback loops, the
linear character of the model as presented implies an inex-
orable move from research to translation to impacts and
does not easily recognise or capture the fact that transla-
tions at some key points requires work to cross over from
one track of work and people to another.
In response to these concerns about the process
marker model, we undertook further methodological de-
velopment, as described below.
Devising a matrix with multiple tracks to present the case
study material
We aimed to develop an approach that would allow the
presentation of data about multiple tracks (or stages or
phases) in the translation of research into healthcare im-
provements in a way that was not simply linear. These
tracks/stages/phases have some similarities with some of
the markers in the top level of Trochim et al.’s model [16],
but aim to recognise the importance of incorporating
scope for overlaps. We considered each of the major steps
in the process of translation from early research through
to adoption in the healthcare system, and attempted to
build them into a matrix that could be applied to the
various fields of research and types of intervention. The
matrix (Figure 1) was refined in response to the emerging
findings from the case studies, and further iterations be-
tween team members. It consists of four main groups of
tracks, two of which contain the research (discovery re-
search and human research/research review) and two of
which cover the clinical practice and public policy devel-
opments. The two middle groups each consist of a num-
ber of separate tracks.
As shown in the Figure, some tracks (for example dis-
covery research, research review and synthesis, policy de-
velopment, and clinical practice) have an ongoing “life” of
their own with activity in the track often pre-dating and
continuing after key events that cause work on a specific
intervention to commence or cross from one track to an-
other. For example, discovery research not only pre-dates
the development of an intervention for human use, but
continues after an initial intervention has been developed
and entered into testing, and may continue to influence
the development of that intervention. Similarly, policy on
clinical practice may pre-date the arrival of a specific
intervention, will develop or adapt in the light of in-
creasing evidence on the effectiveness of that interven-
tion, and will continue to develop even after evidence
on the intervention is completed, as newer interventions
or approaches come on stream. In practice, as illustrated
on Figure 1, some intervention-specific tracks such as
“effectiveness/post-launch research” might well continue
after the “later” tracks in the matrix have started so it is
likely there will be various overlaps in the tracks in the
matrix from any specific intervention.
A model of this kind facilitates analysis of time lags,
and policy responses to them, by allowing consideration
of two linked issues. These are the time and actions re-
quired to move research and its translation i) along any
particular track, and ii) from one track to another. It can
also facilitate demonstration of examples where the trans-
lation process might stall and need to move back down to
a lower track for the work required to overcome the bar-
riers encountered.
Identifying markers/calibration points
We started by exploring a wide range of possible markers
(that is: milestones or events) from both Trochim et al.
[16], who had stated that their quite extensive list of
markers was only illustrative, and a range of other sources.
We identified a long list of nearly 200 potential markers
from Trochim et al. [16] and a range of other papers
[15,17,26-29], and reviewed it, removing (near) duplicates
and adding to the list as the team saw fit. In the first iter-
ation we reduced the list to around 130. While it was clear
that this list would need to be further reduced, the applic-
ability of the general approach was tested by attempting to
apply some of the key markers to data that had been gath-
ered by some of the team members in a previous payback
case study. This was an analysis of the impact from the
early research conducted by Mont Liggins on the use of
corticosteroids for the prevention of respiratory distress
syndrome when pre-term delivery was expected [27].
This initial test of the applicability of the general
approach was reasonably positive, and encouraged us to
develop the approach further. It was clear that, with the
resources available for data collection, the number of
markers would have to be slimmed down. In finalising the
shortened list, we balanced three main criteria in selecting
what we called calibration points. As far as possible they
should be: unambiguous in terms of having a clear date;
key points for measuring time lags and understanding
their nature (and, if possible, for helping identify their
causes); and obtainable from information that is generally
available. Most of the markers in the long list could, as
noted above, be “operationalized as a specific date”. There-
fore, they often already had the quality of meeting our
definition of being unambiguous. In selecting calibration
points, a balance of the other criteria was also important,
with the ability to identify a start point for each track in-
creasingly recognised as being particularly important.
Wherever possible, we looked to identify the calibration
points from among the markers at the highest of
Trochim’s three levels [16], and for the implementation
tracks we also drew on the expertise of team members
to confirm the most appropriate calibration points. We
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Clinical practice using the intervention
Reimbursement/financial support
National policy announcement/guidelines/advice 
Regulatory approval/first non-research use in  
patients and monitoring 
Research review & synthesis on effectiveness & safety 
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Efficacy (Phase III)
Dosage/design (Phase II)
First in human/ 
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Legend
Complete non-research 
tracks of interest, or the 
parts of longer tracks 
that are relevant for the 
interventions on which 
we are focusing. 
Complete research  
tracks of interest, or the 
parts of longer tracks 
that are relevant for the 
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Figure 1 Conceptual matrix for measuring and understanding time lags.
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present our final list of 11 calibration points below,
where they are arranged in a way that reflects the tracks
from the matrix in Figure 1. It is important to note that
some of the calibration points will re-occur in several
different research tracks, and some calibration points
might occur more than once in the same track. Also, we
separately list two different types of review paper.
Final list of 11 calibration points selected for use in the case
studies (linked to tracks from the matrix)
Research tracks (i.e., non-human; human or sub-divisions;
research review and synthesis)
i. Start point of key research study: date proposal
submitted to external funder, or often internal if
pharmaceutical studies, etc.
ii. Start of data collection: date of first patient
recruited, or equivalent in basic research (this could
be an alternative start point of key research study if
proposal is not available).
iii. Date of main publication of study findings: could be
more than one for same body of research where
more than one has been significant in translation or
in the timeline; also could include an equivalent
presentation of findings from basic research conducted
in companies where no formal publications occur.
iv. Patents: date of filing and approval (first, and UK if
different).
v. Date of key review paper: key review of basic or
early research seen as a crucial step in translation.
vi. Date of internationally recognised systematic review
of randomised controlled trials (RCTs) or equivalent
(need to include the first, and the first in the UK if
different and relevant for implementation, and also
others if they are particularly relevant in
implementation).
Non-research or implementation tracks
vii. Date of regulatory approval for UK, from the
relevant body.
viii. Date of first use in UK patients in a routine/
non-research context: which can be launch in UK/
first sale where the technology is sold in the UK.
ix. Date of announcement about national policy to
introduce intervention, or guideline/advice issued:
need to include the first guideline relevant in the
UK, and also others – UK or international – if
they are particularly relevant in implementation,
including key updates.
x. Date of announcement about UK policy to
reimburse or provide financial support:
reimbursement decisions can be identified where
publication of a NICE technology appraisal.
xi. Intervention becomes standard practice: will vary
by intervention.
Our approach facilitated the collection of international
data, especially for the research tracks. Data for the im-
plementation/health service tracks focused primarily on
markers and calibration points relevant to the UK. We
discuss the implications of this later.
Undertaking the case studies
Selection of case studies
We planned to select six case studies, three from each
of CVD and mental health. These were the two medical
fields on which we focused in previous studies, firstly to
assess the value of UK medical research [3], and sec-
ondly, to analyse the range of impacts from medical re-
search [30]. We selected our case studies to include key
examples of UK-funded research. In each field we aimed
to select a range of interventions, so that overall we in-
cluded examples of pharmaceuticals, screening, public
health, psychosocial behavioural interventions, and ser-
vice organisation/complex interventions. In addition to
these criteria, we also wanted to make as rapid progress
as possible in this exploratory study and, therefore,
identified case studies where we had reason to think we
could make progress. We identified two pharmaceutical
examples where there had been important UK research,
and initial correspondence with contacts in the industry
indicated the feasibility of these studies. In CVD, we
selected abdominal aortic aneurysm (AAA) screening as a
stream of research with a major element of Medical Re-
search Council (MRC) funding plus involvement of team
members, and smoking reduction as an area that over-
lapped with team members’ earlier work on the value of
medical research [3]. In mental health, we drew on exam-
ples from the Mental Health Retrosight project being con-
ducted by RAND Europe members of the team to assess
the impact of examples of mental health research [31]. It
became clear that the mental health case study on cogni-
tive behavioural therapy (CBT), which was considering
two applications (in depression and in schizophrenia), was
more appropriately presented as two separate case studies,
thus giving a total of four mental health case studies. Our
seven selected case studies are shown in Table 1.
Data collection
We tested three different approaches for collecting case
study data. The first approach broadly replicated that
adopted previously in payback studies and involved archival
and documentary review and interviews [23-25]. Second,
for the pharmaceutical studies, we collected information
from several sources, including contacts in the pharma-
ceutical industry, publications, and reports of court cases
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about patent disputes (this last, a key source that emerged
during the conduct of the case studies). Third, a biblio-
metric approach was used, where appropriate, to identify
publications from key research studies and then to exam-
ine key systematic reviews and guidelines from the
National Institute for Health and Care Excellence (NICE).
This approach was applied in case studies derived from
the Mental Health Retrosight project [31], where it was
possible to build on case studies in which at least some of
the key research studies had already been identified.
Analysis
We had assumed it would be difficult to draw robust
policy conclusions from analysis of seven case studies,
but thought nonetheless that it was important to see if
the methods being developed had the potential to in-
form policies, and what further methodological steps
might be necessary to allow studies to be undertaken to
support valid conclusions about policy. To do this we
undertook several steps. First, team members considered
the set of case studies and attempted to draw out lessons
about the nature and causes of any time lags identified,
and about the methods used to assess those time lags.
SH then synthesised the comments from team members.
These approaches were supplemented by a quantitative
analysis conducted by SG of the time elapsed in each
case study. For this she used the various tracks identified
in the matrix (Figure 1) and attempted in each case study
to identify the time spent on each track before activity in
the next track started.
Data from the review of literature and policy docu-
ments, the case studies, the synthesis, and the quantitative
analysis were brought together for consideration at team
meetings and at a seminar held at the Office of Health
Economics at which an audience of stakeholders from aca-
demia, industry, and policy advisers was invited to com-
ment on the emerging findings.
The necessary ethical approval for the study, in which
a series of interviews were planned, was obtained from
Brunel University’s Ethics Committee.
Results and discussion
The key findings from the reviews of the literature and
the policy documents, and from the case studies, are set
out below in turn, with further details available in the
relevant Additional files. We then report and discuss the
findings related to the analysis of the objectives set out
in the Background, including making recommendations
for future possible work. As this is a methodological study,
a range of limitations are discussed at various points as
they arise in the analysis.
Reviews of the literature on estimations of time lags and
potential policy responses to the problem of excessive
time lags
The findings from the literature review are similar to those
in Morris et al. [15], in that the papers we identified do
not measure time lags in a comparable way. Importantly,
all of the studies we identified focus on pharmaceutical
R&D, making it easier to compare the methodologies used
by the authors to estimate the time lags. However, this
also implies that any conclusion derived from this litera-
ture review might be specific to case studies of medicines
and might not apply to the development even of other
commercially produced treatments, let alone other areas
of biomedical and health research and development. The
full review is presented as Additional file 1.
Despite the specific focus on medicines, it is still the
case that there was no general agreement on which start
point to consider. One of the reasons why some authors
prefer to consider preclinical and clinical start points, ig-
noring a significant part of the R&D needed to bring a
drug to the market, is that there are several potential ways
to trace the birth of a product idea [32], and so the defin-
ition can be arbitrary and require additional specification.
Chandy et al. [32] found that the mean time between
patent filing and product launch varies considerably ac-
cording to the therapeutic area. The mean time ranges
from 8.5 years for anti-infectives to 15 for immunological
medicines. This result may be due to scientific barriers to
technical development in a particular therapeutic area and
also to specific regulatory policies to favour the research
in areas of great unmet need. This suggests that even
studies using the same time points to estimate the devel-
opment lags of drugs may produce very different results
depending on the set of medicines analysed.
Table 1 Seven selected case studies
Case
study
Cardiovascular
disease
Mental health Type of
intervention
One Calcium channel
blocker –
amlodipine
Pharmaceutical
Two Atypical
antipsychotic –
olanzapine
Pharmaceutical
Three Screening for
abdominal aortic
aneurysms
Screening
Four Smoking
reduction
Other public
health
Five Cognitive behavioural
therapy for depression
Psychosocial
Six Cognitive behavioural
therapy for schizophrenia
Psychosocial
Seven Early intervention for
schizophrenia (or “early
intervention”)
Service
configuration
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We found from our review that there is more homogen-
eity in choice of end points, which usually refer to the easier
to record licensing process. This more common end point,
however, occurs somewhat earlier in the whole translation
process than the end point indicated in Trochim et al.’s
model, or included in our matrix. Mestre-Ferrandiz et al.
[17] compared the intervals between the preclinical and
clinical milestones used by the Centre for Medicines Re-
search International with the more standard Phase I to III
trials. The literature review thus provides additional analysis
that highlights the variety of approaches used in previous
assessments of time lags, and reinforces that it is still a rela-
tively underdeveloped field.
In the review of policy documents, we identified a range
of reports as being relevant since they discussed issues re-
lated to time lags. Those that highlighted key time lags
[1,33-44] are summarised in Figure 2, in which the lags
are organised according to the matrix we developed and
described earlier in the project (Figure 1). Additional file 2
includes the full review of these policy documents.
Although these lags covered the full range of “tracks”
we described in our matrix, many of the documents fo-
cused particularly on the challenges of conducting hu-
man research, including delays in starting clinical trials,
difficulties in collaborating within the healthcare system,
and the complexity of regulation in this area. A second
area of focus was the time taken for new medicines and
technologies to become widely available, both in terms
of the time taken for approval or appraisal by NICE, and
slow subsequent uptake in the National Health Service.
A range of measures, both actual and aspirational,
aimed at reducing lags was also discussed in these docu-
ments. These measures included creating structures to
facilitate collaboration, streamlining legislation, and a
consideration of the incentives for different stakeholders
to participate in biomedical and health R&D. In some
cases policy changes have already been made to intro-
duce proposed measures.
The case studies
We wrote up each of the completed seven case studies
according to an overall common framework starting
with a brief narrative account including i) a definition of
the intervention and its role, and the background to its
development, and ii) key issues related to time lags,
including discussion of any long time lags in the case
study and, where relevant, examples where activities were
undertaken or policies implemented in an attempt to re-
duce time lags. This is followed by a timeline account that
recorded each of the relevant events, for example a trial in
one of the research tracks, and the various markers or
calibration points that could be applied to it. Next there is
a version of the matrix with the various tracks populated
with key events and calibration points from the specific
timeline, and, finally, a reflection on methodological issues
that arose during the conduct of the case study, or in later
consideration of the processes.
The full case studies are available in Additional file 3.
The range of methods used resulted in the collection of
a considerable amount of data. A simplified version of
the matrix from the olanzapine case study is shown below
in Figure 3, in which the activities related to its use also in
the treatment of bipolar disorder are separately identified
for three tracks, and while the full case study develops
various points in more detail, Table 2 illustrates a number
of key points from the case.
Additional file 3 shows how we were able to use the
matrix we developed to present the data from each case
study. In some cases not all the tracks proved to be rele-
vant, but the matrix was at least somewhat applicable to
all seven case studies.
While there were resource problems with collecting
the data on even our more limited range of calibration
points, the pharmaceutical cases in particular identified
novel ways of data collection through the use of pub-
lished information about court cases on patent dis-
putes. It should not be expected that this source of
information will be available in all the cases, but this
does illustrate the important methodological finding
that the framework we developed allows data to be
gathered in innovative ways where opportunities arise.
Furthermore, in the pharmaceutical cases, institutional
arrangements provided some clear milestones for which
dates could be identified, i.e., the patenting and regula-
tory procedures, and using our approach we were able
to take full advantage of this to demonstrate the nature
of the time lags.
Finally, the experience of conducting the case studies
helped us identify a range of considerations, such as, while
the matrix was very useful, it does not allow full presenta-
tion of some key points that have been identified, and
therefore further narrative highlighting of key issues was
required. Further, to identify where policy action will be
most fruitful requires a micro-level analysis of just why a
particular lag occurred and whether that was desirable in
the specific context of the specific technology. As noted,
one of the additional aims of the project was to test the
process marker model proposed by Trochim et al. [16]; it
became clear to us fairly early in the project that the
number of markers in the model would pose unreasonable
challenges in terms of data collection. It also became clear
that each “marker” could occur more than once in a par-
ticular story of development and that the overlap between
different stages could be important in understanding the
process of development. This led to the development of
our own matrix/track structure that we used both for data
collection in the case studies and, as set out below, for data
analysis.
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MATRIX
TRACK
Intervention becomes
standard practice
Reimbursement/
financial support
National policy
announcement/
guidelines/advice
Regulatory approval/
first non-research use
in patients
Research review &
synthesis on
effectiveness & safety
Human
research
Effectiven
ess/ post-
launch
research
Efficacy
(Phase
III)
Dosage/
design
(Phase II)
First in
human/
safety
(Phase I)
Discovery
Cooksey
(2006)
UKCRC
(2008)
IOM
(2004)
BIGT
(2003)
NAO
(2003)
AMS
(2003)
McKinsey
(2005)
IOM
(2010)
IOM
(2008)
Pricing
discussions
Assessing
technology in
practice
Devolved
structure of
NHS
HTAs happen
too late in
drug
development
process
Disincentives
to conduct
research in
the NHS
Poor
dissemination
of clinical
practices
Lengthy drug
approval
times
NICE and
time to
effectively
market drugs
after approval
Time taken to
review
research
proposals
In the UK:
fragmented
trial capacity;
long-start up
times; low
recruitment
rates; high/
variable
costs;
regulatory
constraints;
'less
welcoming
culture'
Slow product
uptake
Poor industry
interface;
fragmented
bureaucracy;
lack of
access to
physicians
and expert
regulators
Office for
Life
Sciences
(2010)
BIS/DH
(2010)
Darzi/DH
(2008)
PICTF
(2009)
NESTA
(2008)
One-off
nature of
clinical trials
results in
long start-up
times
Complexity of
evaluating
new
technologies
– poorly
defined
evidence
needs; need
for early
identification
of beneficial
technologies.
Time taken to
build RCT
evidence
base.
Heightened
expectations
of outcomes
evidence for
drugs.
NICE
appraisal
time
Difficult for
SMEs to
access NHS
procurement
market
Excessively
bureaucratic
processes
for setting
up research
and trials in
some NHS
Trusts and
R&D
departments
Lack of
awareness of
new
technology
Trial start-up
and
completion
times
Firms not
understanding
patients' needs
and how their
technology can
address them
Slow product
uptake
Delayed
NICE
guidance for
new drugs
Trial
recruitment
Lengthy drug
approval
times
Increased
complexity of
clinical trials
and
regulatory
submissions
Different
firms
responsible
at different
stages of
development
POLICY
DOCUMENT
Figure 2 Using the matrix to summarise time lags identified in policy documents.
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Figure 3 Example of a case study matrix: olanzapine.
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Progress in developing methods to improve
measurement and enhance understanding of the diverse
nature and causes of time lags
Analysis of the case studies suggests considerable pro-
gress has been made in developing methods to improve
the measurement and understanding of time lags. The pat-
tern of time lags associated with each intervention could
be identified, organised, and displayed in the narrative
account, timeline, and matrix for each intervention. The
matrix is an advance on the single linear model, and the
need to populate the various tracks within the matrix fo-
cused the data collection. It was possible to explore time
lags along the tracks, in addition to lags arising at the
cross-over points between tracks.
The usual limitations facing many research studies of
achieving a balance between breadth and depth were ex-
emplified in this study because the resources required to
conduct seven case studies were considerable, and yet,
to varying degrees, they may not be complete. The seven
case studies demonstrate the complexity of the issues
addressed, and the variety of circumstances in which
they arise. While a range of interesting and potentially
useful observations can be made, generalisations of any
sort are difficult to make. Below, we first discuss the
progress made in developing ways to measure time lags,
and then progress in enhancing understanding.
Measuring time lags
In all case studies there was a considerable period be-
tween the start of the research and the contribution to
improved health. The time lag is generally longer than
the estimates of time lags reported in the Background
section. There are two main reasons for this. First, at
least some of those studies (for example Grant et al. [13]
and Buxton et al. [3]) reported that 17 years was the aver-
age time lag for all the studies in a body of research cited
in clinical guidelines. We are analysing something differ-
ent and something where one would expect there might
well be longer durations, namely the whole timeline in the
translation of a specific intervention from the initial basic,
or discovery, research through to the health benefits.
Second, when measuring whole timelines there is consid-
erable variety in the points between which time lags are
measured in different studies, and many of the previous
assessments of time lags used a more restrictive definition
for appropriate start and finish points than those on the
full spectrum set out in Trochim et al.’s process marker
model [16].
In our case studies, we attempted to go back to a start-
ing point that seemed as though it would facilitate a rea-
sonably comprehensive analysis. However, inevitably, the
selection of a start point is to some extent arbitrary. The
availability of information, and hence the starting point
for each study, varied and our studies again highlight
that the start point taken for the analysis of time lags
has a major impact on the total duration identified.
In an attempt to give some comparability across the
case studies, our quantitative analysis of the overall time
lag focused on the time lag between “[intervention] dis-
covery” and start of widespread implementation, defining
discovery as the moment at which a clear intervention is
defined and selected for testing. This is typically the point
at which the intervention is linked with the relevant
condition. For a medicine it would be the point at which it
is first synthesised (provided it is synthesised with the
intention to use it for the condition for which it is imple-
mented). In smoking reduction, there are various points
that could be chosen and two examples are presented
herein, one from the first evidence linking smoking and ill
health, and another starting from the first evidence on
passive smoking. The timelines and matrices in some case
studies (as in the matrix for olanzapine contained in
Figure 3) show a period of activity in the discovery track
that preceded the point at which the quantitative analysis
of the time lag classified the intervention as being discov-
ered in the sense of a clear intervention being defined and
selected for testing. The start of widespread implementa-
tion is the point at which a concerted effort at national
policy roll-out occurs in the UK. While the early part of
the matrix covers research internationally, for policy state-
ments and implementation the analysis focuses on the UK
for comparability and to limit the extent of information
gathering required (though the wider approach could
equally well be applied to first policy statements and
implementation internationally). Table 3 demonstrates
how our approach enables measurement of overall time
Table 2 Key points illustrated by the olanzapine case
study
Track Point illustrated
Discovery track Activity in this track continued even after several
human studies had been conducted
Research tracks The publication sources linked to several key events
occurred well after the event itself and sometimes
after activity had already started in the next track:
the publication source for the animal testing was
a later court case over a patent dispute; the Phase I
trial was described in a later account of the stream
of research; and the Phase II trial was described in
a paper published sometime after Phase III had
started
National and
clinical policy
guidelines track
While there may appear to be quite a long delay
between the launch of the medicine in the UK in
1990 and the NICE recommendation in 2002, it
should be remembered that NICE only began
publishing clinical guidelines shortly before 2002
Overall In the case study it has been possible to develop
a matrix to illustrate the movement from the early
research to the NICE recommendation over a
28-year period and involving activity in most of
the tracks
Hanney et al. Health Research Policy and Systems 2015, 13:1 Page 11 of 18
http://www.health-policy-systems.com/content/13/1/1
Table 3 Quantitative summary of time lags – years from “discovery” to UK implementation
Case study topics Overall time lag
in years from
“discovery” to
implementation
(ie not always
counting some
initial discovery
time)
Field:
cardiovascular
disease (CVD) or
mental health
(MH)
Intervention
type
Lag from
“discovery” to
start of first
phase I trial or
human research
Lag from
phase I to start
of first phase II
trial
Lag from
phase II to
start of first
phase III trial
Lag from start
of phase III or
human
research to
first research
review and
synthesis
Lag from
research
review and
synthesis to
first policy
statement
Lag from policy
statement to
implementation
1: Amlodipine 23 years CVD Pharmaceutical 3 1 2 10 7 0
2: Olanzapine 20 years MH Pharmaceutical 4 2 5 5 4 0
3: Abdominal aortic
aneurysm screening
26 years CVD Screening 0 1 5 14 5 1
4a: Smoking reduction:
Evidence on passive
smoking to widespread
bans
39 years CVD Public health 14 n/a n/a 5 19 1
4b: Smoking reduction:
Link between smoking
and ill health to ban on
advertising (Top TV ban,
Bottom widespread ban)
26 years CVD Public health 12 n/a n/a 6 8 0
54 years 30 6
5: Cognitive behavioural
therapy and depression
49 years MH Psychosocial 15 n/a n/a 12 12 10
6: Cognitive behavioural
therapy and schizophrenia
48 years MH Psychosocial 17 n/a n/a 23 0 8
7: Early intervention for
schizophrenia
18 years MH Service
configuration/
Health service
delivery
6 n/a n/a Reviews after
implementation
7 5
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lags in a reasonably consistent manner across case stud-
ies in different fields and looking at different types of
intervention. It is important to note, however, that some
of the numbers on Table 3 are estimates because we are
not sure about the exact dates of key events. Further-
more, in practice, the case studies did not generally get
as far as assessing health gain and this was not included
in the matrix or as a calibration point.
Our approach not only attempts to measure overall
time lags, but also many of the individual elements within
the overall lag. Such measurements help to understand
the nature and causes of the overall time lags, and work
out ways to reduce them. Using a series of key points as
the calibration points, mostly the start of activity on a
series of tracks, Table 3 allows us to measure individual el-
ements within overall time lags. It is possible to use this
approach to make comparative measurements of time lags
across the different stages of the research and implemen-
tation process, drawing on the matrices and the timelines
in the case studies. In some cases a stage is skipped – for
example in “early intervention”, where a policy statement
was made before the first research review and synthesis
was published.
The most significant advance using our new approach
is that while the measurement does go along a track, the
length of the time of the element is not determined by
any fixed point along that track but instead is decided by
when activity in the next track starts. For example, in
the AAA screening case study the community cohort study
was regarded as the equivalent of a Phase II trial [45]. The
study started in 1984 and did not report until 1991, how-
ever, the first RCT that could be viewed as a Phase III trial
began in 1989. Therefore, the time lag element for that
phase was counted as being 5 years rather than 7.
There are implications of the fact that the end point
for the part of each track we measured as contributing
to the overall time lag was not a defined marker, or cali-
bration point (for example, a publication), in relation to
that particular track, but instead was the start of the
next track. First, it means that given as we move along a
track there is no fixed end point for the measurement of
what is counted as being the time lag element of any
track, then the end point dictated by the start of the next
track might occur well before, or well after, the relevant
publication for the original track. Second, it means that
the headings used for the items in the columns on
Table 3 showing the quantitative analysis of elements
within the overall time lag present a somewhat different
picture from that set out in the figure showing the process
marker model in Trochim et al. [16], and described in the
Methods section above.
In order fully to explore this approach we collected
considerable data in the timeline for each case study,
some of which is not shown. In some cases it was useful
to be able to continue showing developments along a
track even after the next track had started. For example,
it is possible that activity in the later track might stall
and further activity might be necessary in the previous
track. Also, as shown in the amlodipine example, devel-
opments might occur in a track such as the post-launch
effectiveness studies that lead to a higher uptake and
move the intervention towards becoming standard prac-
tice (as a first line treatment) well after the date at which
it first appeared in the guidelines or policy track (as a
third line treatment). However, the questions about the
necessity of analysing actions along the continuing track
once actions have started in the next track do raise in-
teresting questions that need further exploration.
Furthermore, within our matrix, we would be able to in-
clude, if thought desirable in future studies, the markers
for items in the lower, more detailed, levels of the process
marker model such as ethics review. It would be quite
likely that the whole of assessment of the time lags in-
volved in an application for ethical approval in any of our
research tracks, for example Phase II, would be completed
before activity started in the next track.
We think that combing a matrix and calibration points
is an important methodological advance, but it cannot
be applied to the same extent across all the types of re-
search. While all the case studies had the same basic
framework and some parallels could usefully be drawn be-
tween them, the quantitative analysis highlights the limita-
tions on how far a uniform approach can be applied.
These limitations are described in the next section be-
cause they can help contribute towards increased under-
standing of the nature of time lags. However, these
observations also point to the importance of considering
the reasons for conducting an analysis of time lags.
Where the aim is to attempt to measure overall lengths
of time lags for a whole portfolio of research (for ex-
ample at a national level) then it might be important to
have consistent start points. Where, however, the focus
is on identifying specific policy actions to reduce time
lags on specific issues then a focus on a specific part of
the overall timeline, for example the ethics approval
process, could be useful and it might not be necessary
to identify the start or the end of an overall timeline for
all the examples included.
Building better understanding of time lags and the diverse
elements that can be involved
In terms of working across fields and interventions, our
observations suggested that differences in patterns of time
lags, and the case studies necessary to study them, might
relate to different types of research in the different fields.
The more complex therapies, such as “early intervention”,
had many, often quite small, RCTs in contrast to other
areas; this tended to be more a feature of mental health
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research than CVD research. Because of these differences,
in some of these cases the full quantitative analysis across a
series of tracks could not be applied (Table 3). Further-
more, there was evidence that for more complex interven-
tions, the time to develop the expertise for implementation
is important. The breadth of the framework we used and
the flexibility we adopted in its application allowed under-
standing of these issues to emerge.
While it was difficult to be precise about all aspects of
time lags, we were able to make observations about how
far some time lags might, or might not, have been reduced
without detriment to the goals of the health and innovation
system. The desirable parts of the overall time lags include
the many steps required in the translation of research to
ensure safety, efficacy, and cost-effectiveness. This does not
only apply to pharmaceutical products. For example, in the
case of AAA screening some large aneurysms might be de-
tected that would not have ruptured and, therefore, some
men will be subjected to serious surgical procedure with
associated risks to prevent ruptures that would not have
occurred. Therefore, it was important to take the time ne-
cessary to conduct a large-scale rigorous trial to determine
whether there would be an overall health gain from the
introduction of AAA screening.
We also identified some undesirable delays within the
case studies, and while generalizable patterns were diffi-
cult to establish, there seem to be more such delays in
the discovery track. Examples include delays in the dis-
covery track of the amlodipine timeline and in both
CBT timelines.
Identifying factors that speed up the translation process
and options for addressing key policy concerns
As noted, it is dangerous to make generalisations from
just seven cases, but some interesting and potentially use-
ful observations about factors that might speed up the
translation process, and areas where it is hoped action
could be taken, do begin to emerge.
In the literature review it was noted that Mestre-
Ferrandiz et al. [17] cited a study by Adams and Brantner
[19], who observed that the development of ‘drugs for
HIV/AIDS have had the shortest Phase III and overall du-
rations’. In this case it is clear how the regulatory policy
may affect the time lag ‘as sponsors have been allowed to
file NDAs [new drug applications to the US Food and
Drug Administration] for almost all AIDS drugs without
completing large-scale human clinical trials’. Here, the
process seems to have been speeded up by the adoption
by the regulator of a different benefit-risk profile in re-
sponse to the particular circumstances posed by HIV/
AIDS and the demands of patients.
A range of suggestions from the documentary review
are highlighted in Figure 2, where the matrix developed
to assist the conduct of the case studies proved to be a
valuable tool to present key elements from the review’s
findings. These are set out more fully in Additional file 2.
A limitation of the study is that the discovery track covers
a wide range of activities and that disaggregation into sep-
arate tracks might allow more meaningful analysis. It
should be noted, however, that during the study we were
unable to come up with a clean and consistent way to
carry out such disaggregation.
We identified various examples of factors that speeded
up the translation process from our seven individual
case studies. For amlodipine there were two important
steps with the ASCOT trial [46] that speeded up transla-
tion. First, once the trial was stopped early because of
the significantly higher mortality for patients in the
other arm of the trial, the researchers completed the
analysis and secured publication rapidly. [It should be
noted that our analysis of this example was only possible
because of the collection of data, such as the end-date
for the trial, which was included in the list of markers
from Trochim et al. [16], but was not included in our
slimmed down list of calibration points, thus highlight-
ing the need for flexibility]. Second, NICE announced it
was going to speed up the revision of its guideline in the
light of the anticipated results from the ASCOT trial,
and applied the policy that allowed it to reduce the time
between guideline revisions in the light of strong new
evidence [47]. The latter example involved the policy sys-
tem prioritising one therapy in particular circumstances.
However, such initiatives could presumably only be used
more widely if more resources were made available for
bodies such as NICE. In the CBT cases, there were delays
in implementation in the National Health Service because
of the lack of trained therapists. Attempts to speed the
process were made through investments in training more
CBT practitioners through the Improving Access to Psy-
chological Therapies initiative. Thus, additional resources
were important once again.
Different patterns of the time elapsed in different case
studies seem to reflect the different drivers of the process.
With the pharmaceutical examples, especially once the
process got as far as the human research tracks, there was
considerable commercial pressure to move quickly. For
example, when the company knew that Phase III trials
for olanzapine were successful, it developed and imple-
mented a global strategy for regulatory submission and
approval aimed to speed up the launch in the market.
There were probably fewer such direct drivers in the
non-pharmaceutical cases, although the extensive work
of one research team in the AAA case helped push the
research along and the research team also played a part
in driving some elements of the policy and implementa-
tion process as rapidly as possible. Some of the activities
of the MRC as funder of the research also contributed
to the creation of a study with sufficient power to make
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a policy impact that facilitated comprehensive transla-
tion into practice. Perhaps with “early intervention” also
there were champions to drive it forward.
The case studies also help us to highlight factors that
need to be taken into account when considering possible
policy options to reduce time lags. Previous changes in
policy and in the climate of research-funding are likely
to have had some impact on the nature of our findings.
The present is not the same as the past. For example,
NICE was created in April 1999 and did not start produ-
cing guidelines and technology appraisals until 1999/2000,
meaning that some apparent delays in timelines in re-
search findings informing policies might have been allevi-
ated had NICE been in existence earlier. Further, our
focus on a range of different tracks helps emphasise that
the causes of time lags, and the appropriate policy re-
sponses, might well differ in different parts of the overall
timeline. Some of our analysis may demonstrate that
“queues” play an important role in some time lags, i.e.,
time lags may result at least in part from one or a series of
queues for resources, e.g., to conduct research or to obtain
regulatory approval. Furthermore, while with hindsight
there may appear to have been undesirable delays in the
translation of what proved to be an effective intervention,
at the time it was not necessarily clear that the particu-
lar line of discovery research, or particular intervention,
should be given priority over others in the queue. Fi-
nally, while the diversity in the cases meant that various
approaches were explored, it further limited the ability
to make comparisons between different case studies in a
way that might be used to inform policy. The heterogen-
eity across the seven case studies suggests a larger num-
ber of such cases might need to be developed to make
robust policy observations, and that if only a few further
studies could be conducted, then the most realistic ap-
proach would be to compare similar interventions, for
example case studies of pharmaceuticals.
Recommendations for further work
We first make some general recommendations about
clarifying terminology, refining the matrix and considering
the implications of the potential increase in availability of
data. Then we discuss three ways in which research in this
area could be further developed and applied to improve
understanding of the time taken to move from invention
to health and other benefits. Future studies to take the
stream of work further will require careful planning in
terms of objectives of the studies and the resources avail-
able to conduct them.
Clarifying terminology
Many components of overall time lags are necessary or
desirable steps to ensure safety, efficacy, and effective-
ness. Hence, we concluded that it will be preferable in
future studies to use the generic term “time elapsed” to
describe the overall time, and reserve the phrase “time
lags” to describe the undesirable delays that might arise
and that might be reduced if appropriate policies can be
identified and introduced. We also debated the best term
to use to describe the stages or phases of the matrix, and
decided “tracks” had the advantage over other potential
terms, such as streams, because it did not imply auto-
matic movement in one-direction only. We recommend
that this term be retained in future studies.
Further work to develop the matrix
A key area in which the matrix could be further refined
is the track for discovery research. Analysis of this track
would be easier if there was the development of a more
disaggregated approach. The motivation for the research
could be a key factor determining how the resulting dis-
aggregated tracks are defined.
Exploiting the increasing availability of data
One common problem facing all of the proposals set out
below, though in differing ways, would be how to find
the appropriate balance between conducting a sufficient
number of case studies to be able to make some general-
isations, and drilling down in sufficient detail in each
one to gather meaningful data. There are, however, vari-
ous recently established sources of routine data that it
might be possible to exploit in future. There will be an in-
creasing availability of relevant data from sources. These
include Researchfish, which is being used in the UK by the
MRC and other research funders [48] (and the earlier
e-Val and NIHR Awards Assessment Tool data collec-
tion), and also the increasing demands from journals for
key dates in research studies to be included in publica-
tions. In principle, such sources could be drawn upon in
any of the proposals for further studies set out below,
but it would be important to explore how far stake-
holders, for example the pharmaceutical industry, might
already have access to some relevant data, and whether
they would be willing to make the data available for the
proposed analyses.
Areas for further possible work
Below, we set out three possible areas for future work
that were informed by our analysis and consultation with
stakeholders. These studies could probably be conducted
in any country and could adopt a similar approach of using
the international evidence for the research tracks and do-
mestic material for the implementation/policy tracks.
Further work to understand the overall pattern of
elapsed time and analyse areas of greatest undesirable
delays or lags At the seminar we ran there was clear
support for an extension of the current case studies to a
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much broader set, provided a consortium of funders
could be mobilised. Such case studies would apply the
matrix and as full a set of calibration points as possible,
and would also provide an opportunity further to valid-
ate the multi-track matrix.
Studies using data mining and bibliometric approaches
This proposal relates to a long-term ambition of this type
of work to be able to assess the elapsed time for a large
number of interventions in order to understand the char-
acteristics associated with “fast” or “slow” translation. To
assess this number of interventions would require an au-
tomated – and hence lower cost – approach. Currently,
there are interesting advances in data-mining techniques
employing bibliometric data that may be worth further ex-
ploration. For example, topic models take a statistical ap-
proach to looking at large corpuses of textual information.
Suites of algorithms have been developed for discovering
the main scientific themes in the journal Science between
1880 and 2002 [49]. If such approaches could be adapted
to capture time information then it may be possible to
automatically extract some calibration points from the
literature using the advanced data mining techniques. If
overall variations were identified through such studies this
might lead to some policy responses to boost the factors
associated with faster translation and to tackle obstacles
associated with slow translation.
A focus on specific small sections of the matrix Some-
what in line with the thinking and practice of Trochim
et al. [16], there might be scope for studies that accept
the overall matrix concept but focus on a series of de-
tailed studies of a particular small part of the overall
matrix. The aim here would be to collate data on a rea-
sonably large number of cases but on a highly specific
issue so as to identify the patterns of elapsed time in-
volved in a specific segment of the timeline. This could
be repeated in a number of small segments where there
might be undesirable delays that could be addressed by
specific policies or actions, e.g., to speed up the ethics re-
view process, and shave time off the processes. If the time
could be reduced, even by small amounts, in each of these
steps, the overall time saved could be important. This type
of approach would be of value to all stakeholders, but
perhaps especially to the pharmaceutical industry, and
perhaps the industry could therefore collectively be en-
couraged to collate the data from a number of their
previous medicine development timelines. The proposal
suggested here might provide a framework in which the
existing data could be exploited more fully, and gaps in
the data could be identified and efforts concentrated on
collecting the additional data that would be of most value.
Conclusions
We have made methodological advances in conceptualis-
ing how best to present analyses of elapsed time. The
development and use of the multi-track matrix, as op-
posed to the single-track linear model, allows the data to
be organised and presented in a way that supports ana-
lysis and understanding of time lags, provided it is used
in conjunction with a narrative account interpreting key
aspects and highlighting issues that are difficult to display.
In particular, it has been important to demonstrate ways
of measuring elements of the overall elapsed time by con-
sidering the time spent in each track before the cross-over
to the start of activity in the next track. These advances
provide a firm basis for further methodological work.
Overall, our approach has enabled us to demonstrate
that the nature of elapsed time is often complex. While the
total elapsed time is lengthy in all cases, and the start point
and end point taken have a major impact on the total time
identified, in some cases specific elements have been
shown on the matrix, and reported in the quantitative
analysis, as having been conducted rapidly. For example,
the research phases in the amlodipine case were pushed
through quickly by the company, and Phase III of the AAA
screening case study started before Phase II had been com-
pleted or the publication related to it had been published.
It has been possible to identify a range of factors that
have speeded up the translation in particular cases. While
it is difficult to make generalisations from seven cases, we
supplemented the case study data with some analysis from
the literature and documentary reviews. We were also able
to identify factors that need to be taken into consideration
when identifying how to use studies to inform policy dis-
cussions on these topics.
Demonstrating the complexities has been useful, but it
has also been resource-intensive. Such resource-intensity
constrains the analysis that can be undertaken in the
future, but it also means that any future studies would
be most efficient if they build on previous work. The
differences between types of intervention (sometimes
exacerbated by differences between research traditions
and regulatory requirements in different medical fields)
mean that while it will, in our view, be useful to apply
the matrix to all future studies, it is important to retain
flexibility in how it is applied.
Finally, we have emphasised the need to distinguish be-
tween elapsed time and undesirable delays: certain periods
of time are necessary or desirable in the translation of re-
search to ensure the safety, efficacy, and cost-effectiveness
of treatments. Therefore, we propose the use of more
appropriate language such as the term “elapsed time” to
describe any period other than those which seem to have
involved undesirable delays. We have also developed the
term “track of activity” to apply in the matrix. We recom-
mend that these terms be used in future studies, including
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ones in the various possible areas in which we identified
scope for taking the work forward.
Additional files
Additional file 1: Literature review on time lags in areas relevant to
the private sector. This file contains a full account of the brief literature
review of areas relevant to the private sector that had not been included
in the earlier review by Morris et al. [15].
Additional file 2: Review of policy documents to identify the time
lags highlighted. This file contains the full review of UK (and other key)
policy documents that was conducted to identify perceived reasons for
time lags and the policy measures proposed to address them.
Additional file 3: Seven case studies of time lags between
conducting medical research and its translation. This file contains all
seven case studies in full; each consisting of a brief narrative account, a
timeline, a version of the matrix, and a reflection on methodological
issues that arose.
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